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Abstract
The prevalence of pretreatment resistance to non-nucleoside reverse transcriptase inhibitors (NNRTis) is >10% in many 
low-income countries. As a consequence, several sub-Saharan African countries have implemented, or are considering 
the introduction of, non-NNRTi-based first-line antiretroviral therapy (ART) for treatment-naïve and treatment-experienced 
patients. This is occurring at a time when ART programmes are expanding, in response to the world Health Organization 
guidelines, which recommend ART initiation regardless of CD4 cell count. Both those developments raise important 
questions regarding their potential impact on Hiv drug resistance and the impact of Hiv drug resistance on clinical 
outcomes. Those issues are particularly relevant to sub-Saharan Africa, where standardised ART regimens are used and 
where viral load monitoring and resistance testing are often not done routinely. it is therefore essential to forecast the 
impact of the implementation of universal ART, and the introduction of drugs such as dolutegravir to first-line regimens, 
on Hiv drug resistance in order to inform future policies and to help ensure sustainable positive long-term outcomes. 
we discuss important public health considerations regarding Hiv drug resistance, and describe how mathematical modelling, 
combined with real-world data from the four African Regions of the international epidemiology Databases to evaluate 
AiDS consortium, could provide an early warning system for Hiv drug resistance in sub-Saharan Africa.
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Introduction
The widespread emergence and transmission of Hiv drug resist-
ance (HivDR) has impaired the success of the currently recom-
mended first-line antiretroviral therapy (ART) regimens including 
efavirenz in sub-Saharan Africa (SSA). The prevalence of pretreat-
ment non-nucleoside reverse transcriptase inhibitor (NNRTi) 
resistance ranges from 8% in Cameroon to 15% in Uganda [1]. 
As many countries in the region consider shifting to dolutegravir-
containing regimens, surveillance and monitoring of HivDR will 
be key to ensuring the durability of this new drug. The introduc-
tion of universal test-and-treat policies [2] will increase the number 
of individuals on ART from 20 million in mid-2017 to approximately 
30 million by 2020. This rapid expansion of ART programmes 
might impact the occurrence of HivDR, particularly in under-
resourced health systems with little capacity for virological moni-
toring. in this article we discuss important public health 
considerations regarding HivDR in SSA, namely the potential 
impact of universal test-and-treat policies on HivDR, and the 
potential implications of HivDR on the effectiveness of dolute-
gravir-based ART. we also identify gaps in current knowledge, 
and describe how we could address current and future challenges 
in the field using real-world data from the international epidemi-
ology Databases to evaluate AiDS (ieDeA), a large consortium 
of Hiv cohorts, and mathematical modelling.
Universal test-and-treat policies and the 
emergence of HIV drug resistance in  
sub-Saharan Africa
Randomised controlled trials have shown the benefits of early 
ART initiation in terms of individual patient outcomes and a 
reduction in Hiv transmission rates [3,4]. However, there are 
concerns that early ART initiation may increase the prevalence 
of antiretroviral drug resistance owing to compromised adherence, 
as patients who feel healthy might be less likely to be fully adher-
ent [5]. Data regarding the impact of early ART on adherence 
and the development of HivDR are limited and inconsistent. in 
a prospective study of 473 patients from Uganda, those who 
initiated ART with a CD4 cell count ≥250 cells/mm3 were twice 
as likely to have treatment interruptions of >72 hours in the first 
90 days of ART, as assessed by electronic pill bottles. As a con-
sequence, they were nearly three times as likely to have an Hiv 
viral load >400 copies/mL at 120 days than those with CD4 cell 
count <250 cells/mm3 [6]. However, a study of 900 patients 
from South Africa found that CD4 cell count at ART initiation 
was not associated with adherence <95% in the first 12 months 
on ART (assessed by visual analogue scale and pill count) [7]. 
in terms of the impact of early ART initiation on HivDR, in a 
cohort study from europe, patients who initiated ART immediately 
(within 3 months of having a CD4 cell count and viral load meas-
ured while AiDS-free), were slightly more likely to develop drug 
resistance within 7 years than those who initiated ART at CD4 
<500 cells/mm3, or <350 cells/mm3 [8]. in contrast, in the 
HPTN052 trial, which showed decreased Hiv transmission between 
serodiscordant couples with ART initiation at a CD4 cell count 
of 350–550 versus <250 cells/mm3, the risk of drug resistance 
was higher in the delayed versus early ART initiation arm [9].
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These differences in the effect of timing of ART initiation on the 
development of HivDR might be explained by differences in 
adherence: patients in clinical trials are generally more closely 
monitored, and may be more motivated to take treatment than 
those in routine care. Although the evidence that early ART ini-
tiation in itself influences the emergence of HivDR is not com-
pelling, there is reason to believe that the continued expansion 
of ART programmes might result in increased rates of HivDR 
through suboptimal adherence and suboptimal retention in care 
in the context of resource-limited health systems. Along with 
HivDR surveys, adherence monitoring and interventions to improve 
adherence should be studied in more depth in these settings.
Potential implications of HIV drug resistance on 
the success of dolutegravir-based antiretroviral 
therapy in sub-Saharan Africa
in many African countries, the prevalence of pretreatment NNRTi 
resistance mutations is >10%, the world Health Organization’s 
threshold for countries to consider implementing non-NNRTi-
based first-line ART [1,10]. As a consequence, many SSA countries 
have either started or are considering implementation of dolute-
gravir-based first-line ART, although recent concerns regarding 
its safety in early pregnancy may limit its use in women of child-
bearing age [11]. it is anticipated that dolutegravir will be used 
in both ART-naïve and ART-experienced patients; the latter will 
switch from their current NNRTi-based first-line regimens. This 
raises concerns regarding its use in settings where resistance 
testing is not standard of care, and where even viral load moni-
toring may not be performed routinely.
Dolutegravir has a high genetic barrier to resistance and develop-
ment of resistance mutations has not been shown in clinical trials 
of treatment-naïve patients initiating dolutegravir-containing ART 
without pretreatment drug resistance [12,13]. in ART-naïve 
patients, dolutegravir was superior to efavirenz and to ritonavir-
boosted darunavir in terms of virological outcomes, and much 
of that superior efficacy was due to dolutegravir’s better tolerability 
[12,13]. However, in a study of dual therapy with dolutegravir 
and lamivudine in the US, three out of 120 patients had virologi-
cal failure at 24 weeks, and one patient developed resistance 
mutations to both drugs (M184v and R263R/K) [14]. This patient 
was thought to be poorly adherent to ART as his plasma dolute-
gravir concentrations were below the limit of quantification on 
at least one occasion.
in treatment-experienced patients receiving dolutegravir, devel-
opment of HivDR is also uncommon, but has been reported in 
patients on dolutegravir monotherapy. in the DOMONO trial, 
ART-experienced patients who were virologically suppressed 
were randomly allocated to switch to dolutegravir monotherapy 
immediately or at 24 weeks [15]. eight of 95 participants experi-
enced virological failure and three developed integrase resistance 
mutations at 48 weeks. in another clinical trial from Spain, two 
of 31 patients who were randomly allocated to be switched to 
dolutegravir monotherapy developed integrase resistance [16]. 
The authors of both studies concluded that dolutegravir should 
not be used as monotherapy. Of note, ART-experienced patients 
in the studies described above were virologically suppressed at 
baseline, and patients with previously documented HivDR were 
excluded. Routine viral load monitoring is not carried out in many 
SSA countries, so it is likely that many patients will switch to 
dolutegravir-based ART when they are not virologically suppressed. 
The DAwNiNG study, a multicentre trial that randomly allocated 
patients whose first-line ART was failing to receive dolutegravir-
based or protease inhibitor-based ART provides some reassurance 
regarding the use of dolutegravir in patients who are not virologi-
cally suppressed [17]. importantly, all patients had to have at least 
one active nucleoside/nucleotide reverse transcriptase inhibitor 
(NRTi) predicted by resistance testing. Dolutegravir-based ART 
was superior to protease inhibitor-based ART, and no patients in 
the dolutegravir arm developed resistance mutations.
in summary, based on the available evidence, dolutegravir seems 
to be highly effective, both in ART-naïve and ART-experienced 
patients, provided that it is combined with a functional NRTi 
backbone. The TenoRes collaboration, which comprises data from 
clinical trials and observational studies, reported a prevalence 
of tenofovir resistance of 57% (370/654), and a prevalence of 
M184v/i mutation of 61% (401/654) in patients whose first-
line ART regimens including tenofovir were failing [18]. even 
though the high prevalence of NRTi resistance in patients with 
failing first-line ART in SSA may have important implications 
for the use of dolutegravir in settings without viral load moni-
toring, the long-term clinical significance of NRTi resistance in 
patients starting dolutegravir is not yet known. interestingly, Hiv- 
suppressed, treatment-experienced individuals with the M184v 
mutation switching to a dolutegravir/lamivudine dual therapy 
do not seem to have an increased risk of virological failure [19]. 
This finding is supported by results from in vitro studies, which 
showed that the presence of either of the NRTi resistance muta-
tions M184i/v or K65R prevented the development of resistance 
to dolutegravir [20].
Gaps in current knowledge: the place for using 
IeDEA cohort data and mathematical modelling 
to predict and monitor HIV drug resistance in 
sub-Saharan Africa
while treatment guidelines and drug prescribing policy are usually 
based on results from randomised controlled trials, such studies 
often give little insight into the real-world effectiveness of the 
interventions evaluated. Clinical trials usually have strict inclusion 
and exclusion criteria, provide close follow-up and monitoring of 
patients, and adherence is usually better than in routine care. 
Observational cohorts are often able to provide generalisable 
data from many more patients in settings that reflect real-world 
use of interventions. However, in terms of predicting how HivDR 
will affect the success of universal test-and-treat policies and the 
introduction of new drugs to first-line ART regimens in SSA, both 
clinical trials and observational cohorts have limitations. The vast 
majority of studies published to date were conducted in North 
America or europe, in clinical settings that differ substantially 
from SSA. Although we can be confident that dolutegravir-based 
first-line triple therapy will lead to favourable virological outcomes 
in SSA, data on its use among patients whose NNRTi-based 
first-line therapy was failing are insufficient to date.
The scarcity of HivDR surveillance data in resource-limited set-
tings, together with the fact that those data are usually not 
linked with observational cohorts, presents challenges for assessing 
and predicting the transmission of HivDR. Mathematical models 
offer a unique opportunity to bridge this gap [21] by combining 
observational data on rates of Hiv diagnosis, treatment, and 
virological response with cross-sectional HivDR surveillance data 
from local settings. Mathematical models have been used to 
address several key questions regarding HivDR in various popula-
tions, and they are increasingly being used to inform policy 
[2,10,21]. Box 1 and Table 1 briefly discuss several examples.
The African regional cohorts of the ieDeA consortium provide 
the ideal platform to explore many of the outstanding research 
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Box 1. Hiv drug resistance mathematical models
The Hiv Synthesis Model, developed by Phillips et al, captures 
resistance to the different antiretroviral classes and its effect on 
treatment outcome [22-24]. More specifically, it models HivDR in 
terms of the presence or absence of every mutation specific to  
the antiretrovirals in use. Agent-based models such as the Hiv 
Synthesis Model have the advantage of being able to represent 
complex processes, like the process of acquiring resistance 
mutations. However, the drawback of using such models is that 
many assumptions are made but may not be verifiable. This can be 
avoided by using simpler models, such as compartmental models. 
Abbas et al [25], Nichols et al [26], and Supervie et al [27] have 
developed deterministic compartmental models to model Hiv  
drug resistance and calibrated them with data from South Africa, 
Zambia and Botswana, respectively. These three models capture 
resistance in a simpler way than the Hiv Synthesis Model. The 
South African Transmission Model [25] has only two layers 
(absence/presence of resistance) to model resistance, while the 
Hiv-transmission models developed by Nichols et al [28] and 
Supervie et al [27] represent the main resistance mutations (K65R 
and M184v mutations for nucleoside reverse transcriptase 
inhibitors) (Table 1).
Table 1. examples of how mathematical models have been used to 
address key Hiv drug resistance questions:
Model HIV drug resistance questions
Hiv Synthesis Model: 
individual-based model 
calibrated with sub-Saharan 
African data
 • Assessing the impact of viral load 
monitoring on HivDR [29]
 • Predicting the impact of HivDR 
on mortality [24,30]
 • Assessing the effectiveness and 
cost-effectiveness of 
interventions such as 
dolutegravir-based ART in 
settings with a relatively high 
prevalence of HivDR [22,23]
Deterministic 
compartmental model 
calibrated with Ugandan 
and Kenyan data
 • Assessing the impact of increasing 
second-line ART coverage (28); 
and earlier ART initiation (32) on 
HivDR
South African Transmission 
Model: compartmental 
model calibrated to 
replicate the South African 
Hiv-1 epidemic
 • Assessing the impact of PreP on 
HivDR [25]
Macha Hiv Transmission 
model: deterministic 
compartmental model 
calibrated with Zambian 
data
 • Assessing the impact of PreP 
[26] on HivDR
PreP intervention 
Transmission model: 
compartmental model 
integrating PreP and ART 
and calibrated with data 
from Botswana
 • Assessing the impact of PreP on 
HivDR [27]
PreP intervention model: 
compartmental model 
representing the MSM 
population in San Francisco
 • Assessing the impact of PreP on 
HivDR [31]
ART: antiretroviral therapy; HivDR: Hiv drug resistance; MSM: men 
who have sex with men; PreP: pre-exposure prophylaxis
questions highlighted in this article, as they comprise large cohorts 
of patients on ART from 23 countries across west, Central, east, 
and Southern Africa [32]. The Consortium collects routine clinical 
data of patients managed largely in primary healthcare settings, 
and has a strong capacity for data management and analysis, with 
a long track record of research that influences policy. Few cohorts 
measure or collect HivDR data, but many have the infrastructure 
to collect them, provided dedicated funding is available.
we have also recently developed a deterministic compartmental 
mathematical model that comprises three layers: treatment stage 
(e.g. diagnosis, treatment, viral suppression or failure); disease 
progression (represented by CD4 count strata); and the presence/
absence of HivDR (in process for future publication). Disease 
progression at each treatment stage, as well as the transition 
from one treatment stage to another, are estimated from obser-
vational data from the ieDeA Southern Africa cohorts and UNAiDS 
data. The model has the potential to address key questions regard-
ing HivDR in Southern Africa. Specifically, we aim to describe 
time trends and drivers of HivDR, and to estimate how the spread 
of resistance is affected by alternative interventions. For example, 
we could assess the impact of enhanced laboratory monitoring 
(i.e. viral load and resistance testing) on the development of 
acquired drug resistance under universal test-and-treat conditions. 
Furthermore, we aim to assess to what extent changes in ART 
guidelines (e.g. dolutegravir-based first-line ART), can curb the 
transmission of resistance and improve clinical outcomes. As 
described above, a key question in this context is the potential 
impact of NRTi resistance on the effectiveness of dolutegravir-
based ART. Finally, we hope to predict the potential development 
and spread of resistance to dolutegravir. The main difficulty of 
making such a prediction is the lack of long-term data regarding 
the impact of dolutegravir resistance on clinical outcomes. Never-
theless, we believe that, by integrating the accumulating clinical 
data or by making reasonable assumptions on such parameters 
based on comparable processes or settings [33], mathematical 
models will be helpful in providing risk assessments, and identify-
ing key knowledge gaps that should be addressed by clinical, 
epidemiological, and laboratory studies.
Conclusion
Universal test-and-treat policies and the introduction of new 
drugs such as dolutegravir to first-line ART regimens have the 
potential to improve patient outcomes and reduce the transmis-
sion of Hiv in SSA. However, it is important to monitor their 
implementation, and to forecast their effect on the development 
of HivDR. The African regional cohorts of the ieDeA global con-
sortium represent an ideal platform to provide data regarding 
the real-world effectiveness of novel ART strategies and math-
ematical models have the potential to help predict the emergence 
of HivDR in SSA. Such research is essential to ensure positive 
long-term outcomes, and to inform future programmatic and 
policy changes, tailored to local settings.
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